Cash Flow Statement

Daily Values

Growth Metrics

Income Statement

Consolidated Net Income EBIT EBITDA EBT EPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing Operations Income towards Parent Company Net Income towards Common Stockholders Non Operating Income Operating Expenses Operating Income Other Non Operating Income Profit After Tax Research & Development Revenue Selling, General & Administrative Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)

Others

Ratios

Prelude Therapeutics (PRLD) Research & Development (2024 - 2025)

Historic Research & Development for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to $21.7 million.